...joining first-time backers GV and Alexandria Venture Investments and returning investors Arch Venture Partners, Biomatics Capital, Decheng Capital...

...and Sofinnova Ventures co-led VelosBio’s series A round, investing alongside Pappas, Chiesi Ventures, Takeda Ventures and Decheng Capital...

...in the U.S. “China has definitely demonstrated more forward thinking with regard to healthcare expenditure,” Decheng Capital’s...
...said. “China has definitely demonstrated more forward thinking with regard to healthcare expenditure.” Victor Tong, Decheng Capital...

...Global Investors and Wellington Management Company, as well as existing investors Arix Bioscience plc (LSE:ARIX), Decheng Capital...

...company Cue Health Inc. raised $100 million in a series C, which saw participation from Decheng Capital...

...Cancer Society, as well as existing investors Sofinnova Investments, venBio Partners, F-Prime Capital Partners, and Decheng Capital...
...Inc. Merck & Co. Inc. Society for Immunotherapy of Cancer Longitude Capital Novo Holdings A/S Sofinnova Investments Inc. venBio Partners F-Prime Capital Partners Decheng Capital Medicxi...

...led its $260 million series C-2 equity round, which also included RA Capital, Hillhouse Capital, Decheng Capital...

...its 2018 series C, bringing the round to $123 million. The extension was led by Decheng Capital...

...With a $45 million series B round led by Decheng Capital, Mammoth Biosciences is capitalizing on its...

...a series C round led by Madrone Capital Partners with participation by Arch Venture Partners, Decheng Capital...
...investors. The company will use the funds to develop and commercialize its DNA sequencing platform. Decheng Capital...